Information Provided By: 
Fly News Breaks for June 5, 2015
ELOS
Jun 5, 2015 | 07:11 EDT
Brean Capital said Syneron Medical has not been rewarded yet with the valuation it deserves, but believes it can change over the next two quarters as UltraShape units sales improve. The firm also noted the company's patent settlement with Viola, which should add incremental royalty income. Brean Capital reiterated its Buy rating and $18 price target on Syneron Medical shares.
News For ELOS From the Last 2 Days
There are no results for your query ELOS
